An RNA-lipoplex is a particle in which RNA is complexed with lipids. Its behaviour depends on the exact lipids, charge balance and route, so a result for one lipoplex does not transfer to another product.
RNA carries negative charge, and positively charged lipid components can associate with it. RNA-lipoplex names a family of formulations, and the final particle need not be positively charged: net charge depends on the balance of RNA and lipid, the ingredients and the preparation. The naming overlaps with lipid nanoparticles, so the actual composition and properties matter more than the acronym.
In one study of the approach, intravenous RNA-lipoplexes were aimed at dendritic cells by adjusting net charge, without adding a molecular ligand; the particles protected RNA from ribonucleases, were taken up and expressed in dendritic cells and macrophages in lymphoid compartments, and triggered interferon-alpha release from plasmacytoid dendritic cells and macrophages, with antigen-specific T-cell responses and tumour rejection in the authors' in vivo experiments (Kranz and colleagues; the abstract also reports a phase I trial in which three people with melanoma had been treated at a low dose when it was published). An innate-immune signal is not antigen expression, antigen-specific immunity or clinical benefit.
The pancreatic cancer vaccine autogene cevumeran shows how specific a lipoplex product is. In the phase I trial each patient's vaccine held two uridine mRNA strands, each encoding up to 10 neoepitopes, formulated in lipoplex nanoparticles of about 400 nm made from the cationic lipid DOTMA and the phospholipid DOPE, given intravenously (Rojas and colleagues, methods). That trial gave atezolizumab and the vaccine to 16 people and then a modified FOLFIRINOX regimen to 15, so it describes one product within a treatment sequence and neither ranks lipoplexes against lipid nanoparticles nor isolates the vaccine's effect.
A commercial cationic-lipid lipoplex reagent shows how far charge and properties can vary. In vitro, eGFP mRNA lipoplexes formed in pure water measured 98.7 to 121.5 nm by dynamic light scattering and had zeta potentials from -14.4 to -58.7 mV across reagent lots, so a cationic lipid does not guarantee a positive particle, and the value was measured for that preparation, medium and lot (Appelbaum and colleagues; canine retina and cell lines, no cancer setting). The same study separates uptake from expression: after subretinal injection eGFP mRNA was detected in all retinal cell types but protein was limited to the retinal pigment epithelium. A product with the same antigen sequence but different lipids or route is not the same product: particle size and route changed where mRNA LNPs went in mice (Di and colleagues), and the Rojas product is described by its own composition, route and protocol.
For messenger RNA, being inside an endosome is not enough: it must reach the cytosol to be translated. The endosomal-release experiments summarised under lipid nanoparticles used LNPs, not lipoplexes, so they do not by themselves describe a lipoplex.
Showing the technology this term belongs to: mRNA and lipid nanoparticle manufacturing.
Shares Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer, Autogene cevumeran, Personalised neoantigen (mRNA) vaccines.
Shares Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer, Autogene cevumeran, Personalised neoantigen (mRNA) vaccines.
Shares Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer, Autogene cevumeran, Personalised neoantigen (mRNA) vaccines.
Shares mRNA and lipid nanoparticle manufacturing, Personalised neoantigen (mRNA) vaccines.
Shares Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer, Autogene cevumeran, Personalised neoantigen (mRNA) vaccines.
Shares Autogene cevumeran, Personalised neoantigen (mRNA) vaccines.
Shares mRNA and lipid nanoparticle manufacturing, Personalised neoantigen (mRNA) vaccines.
Shares Autogene cevumeran, Personalised neoantigen (mRNA) vaccines.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/